阿哌沙班与华法林门诊治疗VTE的出血及复发VTE比较:时间进程与亚组分析
在180天随访期间、选定时间点及预设亚组中,阿哌沙班较华法林显著降低大出血、临床相关非大出血和复发VTE风险(所有P≤.01)。
要点
- 阿哌沙班较华法林降低大出血风险27%~39%,CRNM出血降低17%~28%。
- 阿哌沙班较华法林降低复发VTE风险25%~39%,各亚组一致。
- 获益在180天随访期间及第21、90、180天时间点均持续存在。
核心结论
- 在VTE门诊治疗患者中,阿哌沙班较华法林(联合肠外抗凝桥接)降低出血和复发VTE风险,且获益在180天内各时间点和亚组中一致。
研究设计与样本
- 回顾性观察性队列研究,使用4个美国私人医疗索赔数据库。
- 采用多变量共享脆弱模型比较180天随访期间、第21/90/180天及亚组(PE伴或不伴DVT、仅DVT、诱发性VTE、非诱发性VTE)的结局。
主要发现
- 在选定随访时间点和上述亚组中,阿哌沙班较华法林调整后大出血风险降低27%~39%(所有P≤.01)。
- 临床相关非大出血风险降低17%~28%(所有P≤.01)。
- 复发VTE风险降低25%~39%(所有P≤.01)。
临床怎么用
- 对于门诊VTE治疗,阿哌沙班较华法林联合肠外抗凝桥接可能提供更低的出血和复发VTE风险,支持其作为优先选择。
局限性
- 回顾性观察性设计可能受残留混杂影响。
- 基于索赔数据库,事件 ascertainment 可能不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the phase 3 trial Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy, apixaban was noninferior to enoxaparin, overlapped and followed by warfarin, in the treatment of venous thromboembolism (VTE) with significantly less bleeding; in a real-world evaluation, risks for bleeding and recurrent VTE were lower with apixaban vs warfarin plus parenteral anticoagulant (PAC) bridge therapy. The present study extends this research by comparing outcomes over time and within selected subgroups. A retrospective observational cohort design and 4 US private health care claims databases were used. Study population included patients who initiated outpatient treatment with apixaban or warfarin (plus PAC bridge therapy) for VTE. Major bleeding, clinically relevant nonmajor (CRNM) bleeding, and recurrent VTE were compared during the 180-day follow-up period, at selected follow-up time points (days 21, 90, 180), and within subgroups (pulmonary embolism [PE] with or without deep vein thrombosis [DVT], DVT only, provoked VTE, unprovoked VTE) using multivariable shared frailty models. Study population consisted of 20 561 apixaban patients and 35 080 warfarin patients; baseline characteristics were comparable. Overall, at selected follow-up time points, and within the aforementioned subgroups, adjusted risks were lower among apixaban vs warfarin patients: major bleeding, by 27% to 39%, CRNM bleeding, by 17% to 28%, and recurrent VTE, by 25% to 39% (all P ≤ .01). In this real-world study of VTE patients, risks of bleeding and recurrent VTE were lower among apixaban (vs warfarin) patients during the 180-day follow-up period, at selected follow-up time points, and within subgroups defined by index VTE episode.
引用
- Weycker D, Wygant GD, Guo JD, et al. Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses. Blood Adv. 2020. PMID: 31990332. doi:10.1182/bloodadvances.2019001081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。